| Basics |
BioCryst Pharmaceuticals, Inc.
Biocryst Pharmaceuticals Inc is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in the infectious and inflammatory diseases. It has its focus on oral treatments for rare diseases.
|
| IPO Date: |
March 4, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.46B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.21 | 3.04%
|
| Avg Daily Range (30 D): |
$0.11 | 1.57%
|
| Avg Daily Range (90 D): |
$0.13 | 1.54%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.54M |
| Avg Daily Volume (30 D): |
4.53M |
| Avg Daily Volume (90 D): |
3.28M |
| Trade Size |
| Avg Trade Size (Sh.): |
177 |
| Avg Trade Size (Sh.) (30 D): |
153 |
| Avg Trade Size (Sh.) (90 D): |
130 |
| Institutional Trades |
| Total Inst.Trades: |
3,837 |
| Avg Inst. Trade: |
$2.25M |
| Avg Inst. Trade (30 D): |
$2.34M |
| Avg Inst. Trade (90 D): |
$2.68M |
| Avg Inst. Trade Volume: |
.28M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.11M |
| Avg Closing Trade (30 D): |
$3.66M |
| Avg Closing Trade (90 D): |
$3.79M |
| Avg Closing Volume: |
378.06K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.18
|
$.02
|
$
|
|
Diluted EPS
|
$-.18
|
$.02
|
$
|
|
Revenue
|
$ 557.51M
|
$ 163.35M
|
$ 145.53M
|
|
Gross Profit
|
$ 540.84M
|
$ 160.56M
|
$ 140.97M
|
|
Net Income / Loss
|
$ -35.71M
|
$ 5.09M
|
$ .03M
|
|
Operating Income / Loss
|
$ 54.2M
|
$ 29.79M
|
$ 21.23M
|
|
Cost of Revenue
|
$ 16.67M
|
$ 2.8M
|
$ 4.57M
|
|
Net Cash Flow
|
$ 24.78M
|
$ -1.9M
|
$ .56M
|
|
PE Ratio
|
|
|
|
|
|
|
